BNP Paribas Financial Markets
GLMD icon

BNP Paribas Financial Markets’s Galmed Pharmaceuticals GLMD Stock Holding History

BNP Paribas Financial Markets’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75
Closed -$294 – 6009
2026
Q1 		$294 Sell
75
-38
-34% -$205 ﹤0.01% 5592
2025
Q4 		$675 Buy
+113
New +$1.06K ﹤0.01% 5445
2024
Q4 		– Hold
0
– -$7 – 5456
2024
Q3 		– Hold
0
– – – 4124
2023
Q2 		– Sell
-10
Closed -$5.85K – 3956
2023
Q1 		$5.85K Buy
+10
New +$8.59K ﹤0.01% 3576
2022
Q4 		– Sell
-10
Closed -$5.24K – 3898
2022
Q3 		$4.45K Buy
+10
New +$6.83K ﹤0.01% 4265

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BNP Paribas Financial Markets's GLMD Position: Q2 2026 in Review

BNP Paribas Financial Markets sold out of Galmed Pharmaceuticals (GLMD) in Q2 2026, closing a stake of 75 shares — an estimated $294 sold.

BNP Paribas Financial Markets first reported a position in GLMD in Q3 2022 and held it in 4 quarters. The position peaked at $5.85K in Q1 2023. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • BNP Paribas Financial Markets reported no remaining Galmed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 75 Galmed Pharmaceuticals shares in Q2 2026, an estimated $294.
  • BNP Paribas Financial Markets first reported a position in Galmed Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • BNP Paribas Financial Markets's Galmed Pharmaceuticals position peaked at $5.85K in Q1 2023.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.